Modulation of cGMP-signalling to Prevent Retinal Degeneration

Valeria Marigo, Per Ekström, Frank Schwede, Andreas Rentsch, François Paquet-Durand

Research output: Contribution to journalArticlepeer-review


In the photoreceptors of the retina, the second-messenger molecule cyclic guanosine monophosphate (cGMP) occupies centre stage in the phototransduction cascade. Remarkably, cGMP is also involved in hereditary photoreceptor degeneration caused by a variety of different genetic insults. This provides an entry point for the development of inhibitory cGMP analogues for a mutation-independent treatment. Here, we outline how cGMP signalling can be targeted for the treatment of retinal degeneration, how inhibitory cGMP analogues may be designed and formulated, and how test systems of rising complexity can be used to identify new compounds with photoreceptor neuroprotective properties. In this context, we cite the European Union-funded DRUGSFORD project and provide an example for the efficacy of a specific cGMP analogue to prevent photoreceptor loss and preserve retinal function.

Original languageEnglish
Pages (from-to)88-98
Number of pages11
JournalRSC Drug Discovery Series
Issue number66
Publication statusPublished - 2019

Subject classification (UKÄ)

  • Ophthalmology


Dive into the research topics of 'Modulation of cGMP-signalling to Prevent Retinal Degeneration'. Together they form a unique fingerprint.

Cite this